共查询到20条相似文献,搜索用时 15 毫秒
1.
2.
3.
4.
5.
Ulrich A Walker 《Arthritis research & therapy》2009,11(4):120
A dose-escalating phase II trial studied masitinib, an oral tyrosine kinase inhibitor, in 43 patients with rheumatoid arthritis.
Masitinib induced American College of Rheumatology (ACR)20, ACR50 and ACR70 responses in 54%, 26% and 8% of patients, respectively.
A placebo group was not included. Thirty-seven per cent of the patients withdrew before the 12-week end-point was reached,
primarily because of adverse events. These findings are the first on the efficacy of tyrosine kinase inhibition in a sizeable
population. Future work should focus on delineating the tyrosine kinase that is most important in maintaining rheumatoid activity
and address potential long-term toxicities such as gonadal insufficiency, teratogenicity and cardiotoxicity. 相似文献
6.
7.
8.
9.
Turner E 《PLoS medicine》2005,2(12):e422; author reply e423
10.
11.
12.
16.
17.
18.
19.